Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28). This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I.
BETHLEHEM, Pa., Nov. 7, 2025 /PRNewswire/ -- Following publication of BioProtect's pivotal randomized trial in the International Journal of Radiation Oncology, Biology, Physics (Red Journal) and ...
A randomized controlled trial found that the use of a rectal spacer may help mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy for prostate cancer. HFRT, a ...
Jemperli received FDA breakthrough therapy designation for locally advanced dMMR/MSI-H rectal cancer, following a Fast Track designation in January 2023. The designation aims to expedite development ...
After skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the United States. In fact, one in eight men will be diagnosed with prostate cancer during their lifetime, ...
Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback